Transmission of Drug-Resistant HIV-1 in Europe Remains Limited to Single Classes
April 11, 2008
The objective of the current study was to analyze the "extent and impact of transmission of drug-resistant HIV-1 variants in Europe."
However, resistance was quite extensive in some cases. Four individuals were infected with viruses with reduced susceptibility to all nucleoside reverse transcriptase inhibitors, three to all protease inhibitors and 20 to both NNRTIs. In one individual, the resistance pattern was so extensive that none of currently available antiretroviral was predicted to be fully active.
"The prevalence of TDRM-HIV is quite prominent (9.1 percent) but did not increase in comparison with a large retrospective European study," the report concluded. "Particularly the presence of single NNRTI mutations may impact the efficacy of the first-line regimens. Continuous prospective monitoring remains indicated to explore the patterns and factors contributing to the transmission of TDRMs as well as the potential clinical consequences."
03.12.2008; Vol. 22; No. 5: P. 625-635; The SPREAD Program
This article was provided by CDC National Prevention Information Network. It is a part of the publication CDC HIV/Hepatitis/STD/TB Prevention News Update.